SEC Tracker
Get the app
CTSO · XBRL financial data

Cytosorbents financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CTSO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers———————9,617———9,633
Cost of goods and services sold3,2043,357*3,2163,3924,109(248)*2,5202,8032,8192,430*2,7342,584
Gross profit5,6075,3116,5716,5035,282—6,2086,8146,666—6,1307,049
Research and development3,7494,096*2,2481,5201,851—1,6631,262——1,0251,453
Selling, general and administrative8,1049,242*8,5677,5817,00311,845*8,4329,1678,6109,436*8,1497,964
Total operating expenses12,95714,653*11,4969,9229,67810,816*10,09510,4299,52811,189*9,1749,687
Operating income (loss)(7,350)(9,408)(4,926)(3,419)(4,396)(4,045)*(3,887)(3,615)(2,862)(4,385)*(3,044)(2,638)
Income tax expense (benefit)0(814)*00*0(1,691)*00(401)0*00
Net income (loss)(9,194)(5,835)*(6,358)(4,143)(2,334)(7,884)*(1,478)1,947(3,170)(5,497)*(5,129)(4,417)
Earnings per share, basic USD per share(0.21)(0.12)(0.12)(0.08)(0.04)(0.14)*(0.02)0.03(0.05)(0.09)*(0.08)(0.07)
Earnings per share, diluted USD per share(0.21)(0.12)(0.12)(0.08)(0.04)(0.14)*(0.02)0.03(0.05)(0.09)*(0.08)(0.07)
Weighted average shares, basic thousands of shares44,37446,532*54,26354,30654,45354,713*60,73262,60962,75462,804*62,73962,807
Weighted average shares, diluted thousands of shares44,37446,532*54,26354,30654,45354,713*60,73267,16662,75458,296*62,73962,807

Balance sheet

CSV

Fiscal quarters (CTSO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents8,35914,1318,6088,4595,6853,28011,58710,2047,5366,2494,8134,413
Accounts receivable6,1796,0576,7657,8236,6337,3207,6707,7437,4277,5507,1526,786
Inventory2,9773,6803,7394,3173,2482,7333,0193,7104,0025,2814,4813,686
Prepaid and other current assets1,7461,8348801,3571,0323,2713,1371,3302,3481,5541,311852
Total current assets19,26125,70319,99321,95516,59721,60325,41322,98721,31320,63417,75715,737
Property and equipment, net10,28210,0569,7499,4249,2709,0028,7238,4668,1937,8237,5107,172
Right-of-use asset12,19612,05911,92511,79011,65211,51111,36811,22311,07510,92410,76910,612
Total assets47,57553,26147,07153,42747,80447,37250,78247,99045,75044,18240,56237,960
Accounts payable3,4423,8022,3993,0472,3383,3403,3253,3943,0352,8693,1322,002
Accrued liabilities—498——————————
Current portion of long-term debt8332,5002,500———————6,64614,149
Total current liabilities11,97214,54613,42410,3368,4309,8249,7369,84210,1129,70916,30324,023
Long-term debt4,1992,5431,92913,67313,80613,99614,18714,37714,56716,66710,3133,092
Lease liability, non-current12,89212,89712,79012,68112,56912,44412,31612,18512,05111,90311,75211,596
Total liabilities29,06329,98528,14336,69034,80536,26536,23936,40436,73038,27938,36838,711
Accumulated deficit(276,670)(282,505)(288,863)(293,006)(295,340)(304,009)(305,487)(303,540)(306,710)(312,207)(317,336)(321,754)
Total stockholders' equity18,51223,27518,92816,73712,99911,10714,54311,5869,0205,9032,194(751)
Total liabilities and equity47,57553,26147,07153,42747,80447,37250,78247,99045,75044,18240,56237,960
Common shares outstanding (cover page) thousands of shares44,43954,29454,30654,43054,680≈62,50062,61062,76262,80462,70062,79562,843
  • ≈ Rounded on cover: the filing states this count rounded, and it sits more than 1% off the weighted shares for the period.

Cash flows

CSV

Fiscal quarters (CTSO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,194)(5,835)*(6,358)(4,143)(2,334)(7,884)*(1,478)1,947(3,170)(5,497)*(5,129)(4,417)
Stock-based compensation1,086*843*7349898911,415*818571488886*544368
Net cash from operating activities(5,206)*(6,407)*(4,830)(4,795)*(2,461)*(2,342)*(3,465)(1,510)*(2,577)*(4,825)*(1,162)(583)*
Purchases of property and equipment142*95*4518*152*69*237*17*108*1114*
Net cash from investing activities(258)*(136)*(127)(120)*(298)*(124)*(47)(132)*55*(291)*(46)7*
Proceeds from issuing common stock——53—————————
Proceeds from long-term debt————0*0*———year only——
Repayments of long-term debt——6254,375*0*0*——————
Net cash from financing activities648*12,210*(572)9,835*(99)*167*6,832(1)*0*2,478*——
Net change in cash(4,792)*5,569*(5,523)4,850*(2,773)*(2,405)*3,346(1,384)*(2,668)*(1,287)*(1,436)(400)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cytosorbents4,4139,633(583)*62.8M7.6 quarters 10-QJun 30, 2026
InspireMD15,1491,771(10,895)*46.5M2.8 quarters 10-QJun 30, 2026
Edap TMS21,54213,203(3,691)*37.5M6.5 quarters 10-QJun 30, 2026
Myomo11,21911,705(1,944)*39.6M6.9 quarters 10-QJun 30, 2026
Orchestra BioMed Holdings20,47288(19,332)*60.1M5.7 quarters 10-QJun 30, 2026
Monogram Technologies12,834not reported(2,297)*40.6M5.6 quarters 10-QJun 30, 2025
Pro Dex11,75920,5606,4903.2M— 10-QSep 30, 2026
Sensus Healthcare15,1862,290(3,133)*16.5M4.8 quarters 10-QJun 30, 2026
Spectral AI14,0003,524(4,097)*32.2M3.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.